Abstract
A subset of B cell acute lymphoblastic leukemia (B-ALL) patients will relapse and succumb to therapy-resistant disease. The bone marrow microenvironment may support B-ALL progression and treatment evasion. Utilizing single-cell approaches, we demonstrate B-ALL bone marrow immune microenvironment remodeling upon disease initiation and subsequent re-emergence during conventional chemotherapy. We uncover a role for non-classical monocytes in B-ALL survival, and demonstrate monocyte abundance at B-ALL diagnosis is predictive of pediatric and adult B-ALL patient survival. We show that human B-ALL blasts alter a vascularized microenvironment promoting monocytic differentiation, while depleting leukemia-associated monocytes in B-ALL animal models prolongs disease remission in vivo. Our profiling of the B-ALL immune microenvironment identifies extrinsic regulators of B-ALL survival supporting new immune-based therapeutic approaches for high-risk B-ALL treatment.
Original language | English (US) |
---|---|
Pages (from-to) | 867-882.e12 |
Journal | Cancer Cell |
Volume | 37 |
Issue number | 6 |
DOIs | |
State | Published - Jun 8 2020 |
Keywords
- acute lymphoblastic leukemia
- chemotherapy
- immune microenvironment
- monocytes
- relapse
- single cell
- Prognosis
- Humans
- Child, Preschool
- Infant
- Male
- Case-Control Studies
- Young Adult
- Antineoplastic Agents/pharmacology
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/immunology
- Monocytes/immunology
- Tumor Microenvironment/immunology
- Bone Marrow Transplantation
- Adult
- Female
- Retrospective Studies
- Single-Cell Analysis
- Child
- Proteome/analysis
- Mice, Inbred C57BL
- Survival Rate
- Neoplasm Recurrence, Local/immunology
- Animals
- RNA-Seq
- Adolescent
ASJC Scopus subject areas
- Oncology
- Cancer Research
- Cell Biology